Dashboard
Manage Tickers

CHRS


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

4-biotechnology-stocks-lead-momentum-gains-amid-strong-technicals
4 Biotechnology Stocks Lead Momentum Gains...
10/10/2025 08:32:04

4 biotech stocks—ALDX, ALEC, BDTX, CHRS—show strong week-on-week momentum ranking gains and improving technical indicators.

coherus-oncology-to-present-chs-114-anti-ccr8-data-at-sitc-2025-and-highlight-mechanism-in-cancer-io-webinar-series
Coherus Oncology To Present CHS-114 Anti-C...
10/03/2025 13:10:29

this-brinker-international-analyst-turns-bullish-here-are-top-5-upgrades-for-thursday
This Brinker International Analyst Turns B...
09/04/2025 14:05:42

maxim-group-upgrades-coherus-oncology-to-buy-announces-4-price-target
Maxim Group Upgrades Coherus Oncology to B...
09/04/2025 12:09:18

Maxim Group analyst Jason McCarthy upgrades Coherus Oncology (NASDAQ:CHRS) from Hold to Buy and announces $4 price target.

coherus-biosciences-q2-adj-eps-034-misses-028-estimate-sales-10254m-miss-10946m-estimate
Coherus BioSciences Q2 Adj. EPS $(0.34) Mi...
08/07/2025 21:16:37

Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of...

Core News & Articles
Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

insights-ahead-coherus-biosciencess-quarterly-earnings
Insights Ahead: Coherus BioSciences's Quar...
08/06/2025 21:06:18

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
07/03/2025 21:05:44

coherus-biosciences-announces-clinical-collaboration-with-storm-therapeutics-to-evaluate-stc-15-mettl3-inhibitor-in-combination-with-loqtorzi-next-gen-pd-1-inhibitor-in-phase-1b2-study-for-nsclc-hnscc-melanoma-and-endometrial-cancer-treatment
Coherus BioSciences Announces Clinical Col...
05/27/2025 12:36:21

Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS), today announced a clinical collaboration with STORM Therapeutics, Ltd. ...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
05/13/2025 12:10:18

coherus-biosciences-q1-adj-eps-035-up-from-048-yoy-sales-760m-up-from-231m-yoy
Coherus BioSciences Q1 Adj. EPS $(0.35) Up...
05/12/2025 20:23:29

Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.35) per share. This is a 27.08 percent increase over losses ...

Core News & Articles
Earnings Scheduled For May 12, 2025
05/12/2025 08:32:31

earnings-preview-coherus-biosciences
Earnings Preview: Coherus BioSciences
05/09/2025 20:05:58

hc-wainwright--co-reiterates-buy-on-coherus-biosciences-maintains-7-price-target
HC Wainwright & Co. Reiterates Buy on Cohe...
04/29/2025 10:45:56

HC Wainwright & Co. analyst Douglas Tsao reiterates Coherus BioSciences (NASDAQ:CHRS) with a Buy and maintains $7 price ...

coherus-biosciences-presents-data-from-ongoing-phase-1-clinical-trial-evaluating-chs-114-shows-clinical-efficacy-and-proof-of-mechanism-in-hnscc-in-combination-with-toripalimab
Coherus Biosciences Presents Data From Ong...
04/28/2025 14:12:14

– CHS-114 demonstrates clinical efficacy and proof of mechanism in HNSCC in combination with toripalimab – – Confirmed partial...

coherus-completes-strategic-transformation-with-successful-divestiture-of-udenyca-franchise-says-250m-post-close-cash-balance-extends-cash-runway-over-2-years-into-2027-funding-pipeline-development-through-key-data-catalysts-coherus-to-focus-exclusively-on-its-innovative-novel-oncology-programs
Coherus Completes Strategic Transformation...
04/14/2025 12:11:54

 – $250 million post-close cash balance extends cash runway over two years into 2027, funding pipeline development through key ...

coherus-announces-repurchase-of-170m-of-convertible-notes
Coherus Announces Repurchase Of ~$170M Of ...
04/01/2025 12:06:20

– Remaining $60 Million of outstanding convertible notes to be repurchased post-close of pending UDENYCA divestiture –REDWOOD C...

coherus-to-present-data-from-phase-1-dose-expansion-study-of-chs-114-at-2025-american-association-for-cancer-research-annual-meeting
Coherus To Present Data From Phase 1 Dose ...
03/25/2025 20:31:18

hc-wainwright--co-reiterates-buy-on-coherus-biosciences-maintains-7-price-target
HC Wainwright & Co. Reiterates Buy on Cohe...
03/11/2025 10:27:55

HC Wainwright & Co. analyst Douglas Tsao reiterates Coherus BioSciences (NASDAQ:CHRS) with a Buy and maintains $7 price ...

coherus-biosciences-projects-post-udenyca-close-cash-of-250m-and-cash-runway-projections-exceeding-two-years-past-key-data-readouts-expected-in-2026
Coherus Biosciences Projects Post-UDENYCA-...
03/10/2025 20:15:40

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION